These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 37344839)

  • 1. Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures.
    Wang J; Xie Q; Song H; Chen X; Zhang X; Zhao X; Hao Y; Zhang Y; Li H; Li N; Fan K; Wang X
    J Nanobiotechnology; 2023 Jun; 21(1):200. PubMed ID: 37344839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unveiling the Potential Role of Nanozymes in Combating the COVID-19 Outbreak.
    Ali J; Elahi SN; Ali A; Waseem H; Abid R; Mohamed MM
    Nanomaterials (Basel); 2021 May; 11(5):. PubMed ID: 34069866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.
    Fernandes Q; Inchakalody VP; Merhi M; Mestiri S; Taib N; Moustafa Abo El-Ella D; Bedhiafi T; Raza A; Al-Zaidan L; Mohsen MO; Yousuf Al-Nesf MA; Hssain AA; Yassine HM; Bachmann MF; Uddin S; Dermime S
    Ann Med; 2022 Dec; 54(1):524-540. PubMed ID: 35132910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms.
    Aileni M; Rohela GK; Jogam P; Soujanya S; Zhang B
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19: Progress in diagnostics, therapy and vaccination.
    Liu X; Liu C; Liu G; Luo W; Xia N
    Theranostics; 2020; 10(17):7821-7835. PubMed ID: 32685022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A perspective on SARS-CoV-2 virus-like particles vaccines.
    Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
    Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology-Based Strategies for the Management of COVID-19: Recent Developments and Challenges.
    Singh R; Behera M; Kumari N; Kumar S; Rajput VD; Minkina TM; Adnan M; Siddiqui AJ; Kumar N
    Curr Pharm Des; 2021; 27(41):4197-4211. PubMed ID: 34459371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
    Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
    Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of COVID-19 for controlling the pandemic: A review of the state-of-the-art.
    Taleghani N; Taghipour F
    Biosens Bioelectron; 2021 Feb; 174():112830. PubMed ID: 33339696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2.
    Mufamadi MS; Ngoepe MP; Nobela O; Maluleke N; Phorah B; Methula B; Maseko T; Masebe DI; Mufhandu HT; Katata-Seru LM
    Biomed Res Int; 2023; 2023():4588659. PubMed ID: 37181817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primed for global coronavirus pandemic: Emerging research and clinical outcome.
    Ahamad S; Branch S; Harrelson S; Hussain MK; Saquib M; Khan S
    Eur J Med Chem; 2021 Jan; 209():112862. PubMed ID: 33070079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.
    Forchette L; Sebastian W; Liu T
    Curr Med Sci; 2021 Dec; 41(6):1037-1051. PubMed ID: 34241776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: Vaccines and therapeutics.
    Ponnampalli S; Venkata Suryanarayana Birudukota N; Kamal A
    Bioorg Med Chem Lett; 2022 Nov; 75():128987. PubMed ID: 36113669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
    Noor R
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
    Wiersinga WJ; Rhodes A; Cheng AC; Peacock SJ; Prescott HC
    JAMA; 2020 Aug; 324(8):782-793. PubMed ID: 32648899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.